AIM ImmunoTech Approaches Major Clinical Inflection Point with Phase 2 Pancreatic Cancer Data Expected Q1 2027; Reports Third Quarter 2026 F

Expanding scientific rationale for Ampligen® in the evolving pancreatic cancer treatment landscape, including potential complementary approaches with RAS-targeted therapiesAmpligen dosing completed in Phase 2 DURIPANC study, positioning Company for near-term clinical benefit readout that could help…